AstraZeneca today announced that it has entered into an agreement to buy certain off-label uses for Nexium, a brand name used for gastroesophageal reflux disease (GERD).
The company is also acquiring certain off-label indications for Zyrtec, which is used for asthma and other breathing conditions. The company was previously interested in developing a new product called AstraZeneca’s new anti-inflammatory painkiller Celebrex, which was also indicated for respiratory conditions.
The new Nexium product is expected to be launched in the second quarter of 2023 and will be available for sale by the end of the year. The Nexium product is indicated for treatment of heart failure, heartburn and other gastrointestinal symptoms.
The Nexium product is a product that is marketed by AstraZeneca and sold under the name AstraZeneca Nexium. The company is a global leader in the pharmaceutical industry with a presence in more than 100 countries and a research and development organization (R& D) of over 100,000 professionals. In 2023, the company reported a revenue of $2.6 billion.
AstraZeneca today announced that it has entered into an agreement with GlaxoSmithKline to acquire all rights to the Nexium product. AstraZeneca is an authorized distributor of the brand-name drug. AstraZeneca is committed to providing the pharmaceutical industry with quality medicines and has been a leader in the production and distribution of medicines. The agreement will ensure that AstraZeneca will continue to provide a leading source of pharmaceutical products.
“We have worked hard to build a strong and resilient industry that is resilient and strong in the fight against heart disease and chronic pain,” said Jean-Pierre Garnier, CEO of AstraZeneca. “Through the agreement, we are investing in a path forward in our relationship with GlaxoSmithKline. We are investing in our strong pipeline for the next four years to develop and commercialize more therapies for chronic pain such as Nexium. This is a strategic investment for us, and we are looking forward to working with AstraZeneca to develop our portfolio and to continue to lead its business.”
“AstraZeneca is one of the world’s leading pharmaceutical companies with over 60 million prescriptions written and generated approximately $1.9 billion in sales in 2023. Our innovative approaches to managing pain have been a cornerstone of our growth,” said David Graham, CEO of AstraZeneca. “Through our relationship with GlaxoSmithKline, we are investing in a path forward that will allow us to focus our efforts on providing more affordable and effective pain relief and addressing chronic pain.”
The Nexium product was originally developed as a treatment for chronic cough and other heartburn and acid reflux disease. AstraZeneca has successfully developed several therapies for these conditions, including Nexium and Zyrtec. For more information about AstraZeneca’s partnership with GlaxoSmithKline and how the agreement will support AstraZeneca’s efforts to build a strong and resilient business, please visit.
The Nexium product was developed by AstraZenecaNexium is indicated for treating heartburn, acid reflux disease, heartburn, and other gastrointestinal symptoms in adults and children 12 years of age and older. AstraZeneca has invested approximately $2.1 billion since its launch in 2023 to date. AstraZeneca has a pipeline of therapies for many chronic diseases that includes Zyrtec, Celebrex, Cymbalta, Prozac, Paxil, Raloxifene and other drugs.
AstraZeneca is a global leader in the pharmaceutical industry with a presence in more than 100 countries. Its global research and development organization, AstraZeneca’s R& D group and its portfolio of leading therapies and medicines, provides insights and expert advice to healthcare professionals and patients across all age groups. For more information about AstraZeneca’s partnership with GlaxoSmithKline, visit.
©2025 AstraZeneca PLC
Share this page & moreToday’s news is more than just the latest; it’s a comprehensive guide to the major pharmaceutical news outlets. Read our guide to some of the most important stories in the Week and see our full coverage of the Week.
The following adverse reactions are described in[]andfor each. Allergic reactions (ARs) are defined as an allergic reaction to the drug.
Allergy is defined as the presence of symptoms, which may include:
Uncommon in young children. Common signs of allergy are wheezing and shortness of breath, and symptoms that may be:
Nexium (esomeprazole) is indicated for the treatment of:
Nexium is not indicated for the treatment of acute exacerbations of chronic bronchitis or acute exacerbations of chronic sinusitis (Sinusitis).
Allergy cannot be excluded from treatment in children and adolescents (less than 12 years).
The use of Nexium is contraindicated in patients with known hypersensitivity to any proton-pump inhibitor. For patients with known hypersensitivity to any of the following, see the “Safety Criteria” section:
Adverse reactions in newborns are generally reversible and usually occur within two weeks of birth. However, this can vary based on individual patient characteristics and treatment response to treatment. The most common adverse reactions are headache, nausea, and diarrhea.
For patients with mild to moderate hypersensitivity to one or both proton-pump inhibitors, the drug is usually administered intravenously or orally once a day. However, for hypersensitivity reactions that can occur with chronic use of Nexium, the drug can be given to the patient for up to three days.
The appropriate dose of Nexium is 2.5 to 40 mg once daily. The maximum daily dose is 800 mg. Patients should be treated for an extended period, usually four to six weeks, when necessary. If the patient is not able to tolerate the Nexium dose, the dose can be increased to a maximum of 2000 mg by adding a low-salt salt form of the drug.
For patients with severe hypersensitivity to one or both proton-pump inhibitors, the dose is based on the maximum daily dose. The recommended initial dose is 20 mg per day, divided into two doses, and then extended to a maximum of 40 mg daily based on the patient's response. Patients should be treated for a minimum of four weeks for severe allergic reactions to proton-pump inhibitors, then for six weeks for mild to moderate allergic reactions, and then four weeks for severe allergic reactions.
For patients with moderate to severe allergic responses, the dose is based on the maximum daily dose. Patients should be treated for a minimum of four weeks for severe allergic reactions to proton-pump inhibitors, then for six weeks for mild to moderate allergic reactions, and then for severe allergic reactions.
If the patient is unable to tolerate the Nexium dose, the dose can be increased to a maximum of 2000 mg by adding a low-salt form of the drug.
Nexium is a brand ofesomeprazolemedication that belongs to the class oflansoprazolepainkillers. This medication treatsexcessive body aches and pain associated with:
1. Respiratory, thoracic and lumbago pain
2. Uterus meningitis
3. Pneumonia
4. Myocardial infarction and stroke
5. Ischemic optic neuropathy
Nexium works by blocking the effects of acid in the stomach, thereby helping to reduce the amount of stomach acid produced. It is taken as directed, and the tablet is then taken up to one hour before you expect to be feeling well. After this, it is important to continue taking the medication as prescribed to ensure that it is still pain-free for the entire length of your day.
When you take Nexium, you are taking(an acid blocker) for the management of an excess amount of stomach pain. It is also used to reduce the chances of having a heart attack or stroke. When you are taking Nexium, you are taking(anantibiotic) for the prevention of the development of ulcers in the stomach and intestine. You should also be takingantacid) for the relief of stomach pain.antacid) for the relief of abdominal pain.antacid) for the relief of menstrual cramps.
The most commonly reported adverse reactions are:
Serious side-effects such as:
Nexium is available in two doses: 50 mg and 100 mg. Swallow the tablet whole with water. Do not chew or crush the tablet. The tablets should be swallowed whole and should not be chewed or crushed. You should also follow your doctor’s instructions on how to take Nexium. Take Nexium on an empty stomach for best results. You should take Nexium with food, but avoid taking it at a time that makes you feel ill. You should also take Nexium with or without food. Nexium should be taken for 14 days.
What is Reflux?
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”) which may become inflamed and painful. This may cause you symptoms such as a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Do I get instant relief from taking a Nexium tablet?
Nexium Control is not meant to bring immediate relief. You may need to take the tablets for 2-3 days in a row before you feel better. You must talk to a doctor if you do not feel better or if you feel worse after 14 days.
How much to take• The recommended dose is one tablet a day. • Do not take more than this recommended dose of one tablet (20 mg) a day, even if you don’t feel an improvement immediately. • You may need to take the tablets for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better. • The treatment length is up to 14 days. • When your reflux symptoms have completely gone you should stop taking this medicine. • If your reflux symptoms get worse or do not improve after taking this medicine for 14 days in a row, you should consult a doctor. If you have persistent or longstanding, frequently recurring symptoms even after treatment with this medicine, you should contact your doctor. Taking this medicine • You can take your tablet at any time of the day either with food or on an empty stomach. • Swallow your tablet whole with half a glass of water. Do not chew or crush the tablet. This is because the tablet contains coated pellets, which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.
Alternative method of taking this medicine• Put the tablet in a glass of still (non-fizzy) water. Do not use any other liquids. • Stir until the tablet breaks up (the mixture will not be clear) then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it. • To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine – do not chew or crush them
Please read the patient information leaflet above to get more information as to side effects, precautions of use etc.
Active Ingredients:
Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium trihydrate)
List of Excipients:
Glycerol monostearate 40-55 HydroxypropylcelluloseHypromellose 2910 (6 mPa-s) Reddish-brown iron oxide (E-172) Yellow iron oxide (E-172)Magnesium stearate Methacrylic acid ethylacrylate copolymer (1: 1) dispersion 30 per cent Cellulose microcrystallineSynthetic Paraffin Macrogol 6000Polysorbate 80 Crospovidone (Type A) Sodium stearyl fumarateSugar spheres (sucrose and maize starch), Talc, Titanium dioxide (E-171) Triethyl citrate
Stackscoop5% w/w Diclofenac sodium 10 mM (Mg)
TabletPeal color: White, with a small amount of yellow iron oxide (E-172)Peal size: 1.25 mm
StoveOil Bachelor’s® (B-3345 Lake Balm) 100% - Deionized Water
Material used in the manufacture of Nexium Control tablets:
Diphenhydramine HCl 10% w/w (Mg)
Injection form: Film forming Agent: WaterExcipient: Talc, D& C Yellow No. 10
Always consult your doctor or pharmacist before using this product. Keep all appointments.
Stade de France Pharmacy